Cargando…
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and phosphorylation of downstream substrates including phosph...
Autores principales: | Nicolson, Phillip L.R., Hughes, Craig E., Watson, Stephanie, Nock, Sophie H., Hardy, Alexander T., Watson, Callum N., Montague, Samantha J., Clifford, Hayley, Huissoon, Aarnoud P., Malcor, Jean-Daniel, Thomas, Mark R., Pollitt, Alice Y., Tomlinson, Michael G., Pratt, Guy, Watson, Steve P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269309/ https://www.ncbi.nlm.nih.gov/pubmed/30026342 http://dx.doi.org/10.3324/haematol.2018.193391 |
Ejemplares similares
-
Low-dose Btk inhibitors selectively block platelet activation by CLEC-2
por: Nicolson, Phillip L.R., et al.
Publicado: (2020) -
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021) -
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021) -
Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013) -
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)